Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Surgery Partners (SGRY) Share-based Compensation: 2014-2025

Historic Share-based Compensation for Surgery Partners (SGRY) over the last 12 years, with Q3 2025 value amounting to $2.6 million.

  • Surgery Partners' Share-based Compensation fell 6338.03% to $2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.6 million, marking a year-over-year decrease of 4170.62%. This contributed to the annual value of $33.3 million for FY2024, which is 8813.56% up from last year.
  • Per Surgery Partners' latest filing, its Share-based Compensation stood at $2.6 million for Q3 2025, which was down 6338.03% from $6.8 million recorded in Q2 2025.
  • In the past 5 years, Surgery Partners' Share-based Compensation registered a high of $15.1 million during Q2 2024, and its lowest value of $2.6 million during Q3 2025.
  • Moreover, its 5-year median value for Share-based Compensation was $4.6 million (2023), whereas its average is $5.5 million.
  • As far as peak fluctuations go, Surgery Partners' Share-based Compensation skyrocketed by 22826.09% in 2024, and later crashed by 6338.03% in 2025.
  • Over the past 5 years, Surgery Partners' Share-based Compensation (Quarter) stood at $4.0 million in 2021, then soared by 35.0% to $5.4 million in 2022, then dropped by 16.67% to $4.5 million in 2023, then skyrocketed by 37.78% to $6.2 million in 2024, then tumbled by 58.06% to $2.6 million in 2025.
  • Its Share-based Compensation stands at $2.6 million for Q3 2025, versus $6.8 million for Q2 2025 and $7.6 million for Q1 2025.